4//SEC Filing
Kulkarni Samarth 4
Accession 0000950170-25-043975
CIK 0001674416other
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 5:35 PM ET
Size
9.5 KB
Accession
0000950170-25-043975
Insider Transaction Report
Form 4
Kulkarni Samarth
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-03-20−19,688→ 59,062 total→ Common Shares (19,688 underlying) - Exercise/Conversion
Common Shares
2025-03-20+19,688→ 205,116 total - Sale
Common Shares
2025-03-21$41.23/sh−10,031$413,578→ 195,085 total
Holdings
- 85,622(indirect: The Kulkarni 2023 GRAT)
Common Shares
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001682019
Filing Metadata
- Form type
- 4
- Filed
- Mar 23, 8:00 PM ET
- Accepted
- Mar 24, 5:35 PM ET
- Size
- 9.5 KB